Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (CHAARTED / E3805) (2015)

Peer-Reviewed Study · Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS · August 20, 2015

Sweeney CJ et al., 2015-08-20: E3805/CHAARTED randomised 790 men starting androgen deprivation for newly metastatic hormone-sensitive prostate cancer to ADT plus six cycles of docetaxel or ADT alone. Median survival was 57.6 vs 44.0 months (HR 0.61), with the benefit concentrated in high-volume disease.

the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001).

Abstract (RESULTS)

Sweeney CJ et al., 2015-08-20: E3805/CHAARTED randomised 790 men starting androgen deprivation for newly metastatic hormone-sensitive prostate cancer to ADT plus six cycles of docetaxel or ADT alone. Median survival was 57.6 vs 44.0 months (HR 0.61), with the benefit concentrated in high-volume disease. Funder: 'Supported in part by a grant from the National Cancer Institute… Sanofi provided the docetaxel and a grant to ECOG-ACRIN.' Design/analysis: designed in 2005 by ECOG; coordinated by ECOG-ACRIN; the ECOG-ACRIN Statistical Center collected the data and was the data coordinating center – Sanofi did not run or analyse it. Conflicts: NEJM disclosure forms referenced, not printed. Maker: Sanofi (docetaxel). Comparator: ADT alone. Toxicity: grade 3-4 febrile neutropenia 6.2%, infection with neutropenia 2.3%, grade 3 sensory neuropathy 0.5%. Study type: randomized trial.